112253-26-6 Usage
General Description
2-(4-Benzylpiperazino)benzaldehyde is an organic compound that possesses benzaldehyde and piperazine components in its structural composition. Its chemical formula is C19H20N2O, and its molecular weight is 292.37 g/mol. As an aromatic aldehyde, this compound features a benzene ring attached to a formyl group, while the benzylpiperazine moiety is a six-membered ring with two nitrogen atoms. The compound is often used in scientific research and potentially in the development of pharmaceuticals. The exact characteristics and properties may vary depending on things like temperature, pressure and concentration.
Check Digit Verification of cas no
The CAS Registry Mumber 112253-26-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,1,2,2,5 and 3 respectively; the second part has 2 digits, 2 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 112253-26:
(8*1)+(7*1)+(6*2)+(5*2)+(4*5)+(3*3)+(2*2)+(1*6)=76
76 % 10 = 6
So 112253-26-6 is a valid CAS Registry Number.
InChI:InChI=1/C18H20N2O/c21-15-17-8-4-5-9-18(17)20-12-10-19(11-13-20)14-16-6-2-1-3-7-16/h1-9,15H,10-14H2/p+1
112253-26-6Relevant articles and documents
TRPML MODULATORS
-
Paragraph 0746, (2021/06/26)
The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
NOVEL BENZYL(IDENE)-LACTAM DERIVATIVES
-
Page/Page column 30-31, (2008/06/13)
The present invention relates to novel benzyl(idene)-lactam derivatives, compounds of the formula (I) wherein R1 is a group of the formula G1 or G2 depicted below, wherein R1, R3, R6, R13, X, a, n and m are as defined herein, their pharmaceutically acceptable salts, and pharmaceutical compositions which include selective antagonists, inverse agonists and partial agonists of serotonin 1 (5-HT1) receptors, specifically, of one or both of the 5-HT1A and 5-HT1B receptors. The compounds of the invention are useful in treating or preventing depression, anxiety, obsessive compulsive disorder (OCD) and other disorders for which a 5-HT1 agonist or antagonist is indicated and have reduced potential for cardiac side effects, in particular QTc prolongation.
